ADCYAP1R1 is encoded by the ADCYAP1R1 gene (chromosome 7) and exists as multiple isoforms due to alternative splicing. Key structural features include:
Transmembrane domains: 7 transmembrane helices characteristic of class B GPCRs .
Recombinant fragment: Produced as a 21–120 amino acid (aa) fragment in wheat germ, suitable for biochemical assays like SDS-PAGE and ELISA .
Tissue distribution: Expressed in adrenal medulla, pancreas, uterus, brain, and peripheral ganglia .
ADCYAP1R1 binds PACAP-27 and PACAP-38 with high affinity, activating Gαs and Gαq proteins to stimulate downstream effectors:
Adenylyl cyclase: Increases intracellular cAMP, modulating hormone secretion (e.g., ACTH, LH) .
Phospholipase C: Activates via Gαq, generating IP3 and DAG to mobilize calcium and activate PKC .
β-arrestin signaling: Internalizes to endosomes, triggering ERK-mediated pathways .
Neurotransmission: Regulates synaptic plasticity and hippocampal activity .
Stress response: Modulates hypothalamic-pituitary-adrenal (HPA) axis activity .
Metabolism: Influences glucose homeostasis and energy balance .
The SNP rs2267735 in ADCYAP1R1 has been extensively studied for its role in PTSD and anxiety disorders:
Females: CC genotype correlates with PTSD severity and estrogen-regulated PACAP signaling .
Males: Limited evidence for direct PTSD association, but ADCYAP1R1-CRHR1 interactions may influence stress responses .
| Parameter | Value | Source |
|---|---|---|
| Sensitivity | 0.094 ng/ml | |
| Detection Range | 0.156–10 ng/ml | |
| Sample Compatibility | Serum, plasma, lysate |
PTSD: Targeting PACAP-PAC1 signaling to modulate fear circuitry (e.g., reducing amygdala hyperactivity) .
Asthma: Epigenetic modifications of ADCYAP1R1 may offer biomarkers for early intervention .
Hippocampal Excitability: PACAP enhances granule cell excitability via PAC1 receptors, amplifying synaptic responses .
Fear Conditioning: CC carriers exhibit impaired safety signal learning and exaggerated startle responses .
ADCYAP1R1 (also known as PAC1) is a G-protein coupled receptor that shows high-affinity binding to pituitary adenylate cyclase-activating polypeptide (PACAP). This receptor binds PACAP with approximately 1,000-fold higher affinity than other related peptides such as VIP . ADCYAP1R1 serves as the primary mediator of PACAP's neurobiological effects, particularly in stress response pathways and fear processing circuits. The receptor's activation triggers intracellular signaling cascades that regulate neural activity, plasticity, and cellular survival mechanisms.
ADCYAP1R1 shows selective distribution in the brain, with expression patterns that align with its functional roles. Detailed analysis using dual in situ hybridization techniques has revealed:
High expression in the amygdala, a key structure in fear processing
Selective expression in Slc32a1-expressing cells (GABAergic neurons)
This distribution pattern supports ADCYAP1R1's involvement in emotional regulation and stress response, with particular concentration in regions mediating fear and anxiety responses.
For accurate assessment of ADCYAP1R1 expression in neural tissue, researchers should consider:
Sensitive dual in situ hybridization (DISH) methods that enable co-localization with neurochemical markers (e.g., Slc17a7, Slc17a6, and Slc32a1)
Light microscopy with both low- and high-magnification capabilities for precise anatomical localization of expression patterns
Quantitative PCR for mRNA expression analysis, with appropriate controls
For protein analysis, immunohistochemistry with validated antibodies
When genotyping ADCYAP1R1 variants, the following approaches have proven effective:
TaqMan SNP Genotyping Assay with TaqMan GTXpress Master Mix on the ViiA7 Real-Time PCR system
Sequenom SNP genotyping platform using iPlex gold reagents and the MassARRAY system
Recommended quality control measures include:
Within-plate duplicates and non-template controls
Minimum 25% sample duplication across platforms
Verification of Hardy-Weinberg Equilibrium
The rs2267735 polymorphism represents a single nucleotide polymorphism (SNP) in the ADCYAP1R1 gene that has been linked to fear responses and risk for post-traumatic stress disorder (PTSD), particularly in women. Key characteristics include:
Location within a putative estrogen response element, suggesting hormone-dependent effects
Risk genotype (CC) linked to increased amygdala and hippocampal responses to fearful stimuli
Reduction in functional connectivity between amygdala and hippocampus in risk genotype carriers
This polymorphism appears to function as an intermediate phenotype between genetic risk factors and psychiatric outcomes, with ADCYAP1R1 genotype showing larger effects than PTSD diagnosis in some studies .
ADCYAP1R1 modulates neural circuit function through several mechanisms:
Amygdala reactivity:
Circuit connectivity:
Synaptic plasticity:
Sensory integration:
| Brain Region | ADCYAP1R1 Effects | Functional Implications |
|---|---|---|
| Amygdala | Increased reactivity to fear stimuli in risk genotype | Enhanced fear responses, potential PTSD vulnerability |
| Hippocampus | Dense PACAP binding sites, neurotrophic effects | Memory formation, contextual fear processing |
| Amygdala-Hippocampus Circuit | Reduced functional connectivity in risk genotype | Impaired contextual modulation of fear responses |
| Prefrontal-Amygdala Circuit | Involvement in regulation of amygdala reactivity | Emotion regulation deficits in risk carriers |
ADCYAP1R1 demonstrates pronounced sex-specific effects that are particularly relevant to psychiatric research:
The association between ADCYAP1R1 variants and PTSD has been identified primarily in women, not men
The rs2267735 polymorphism is located within a putative estrogen response element
PACAP may influence neural structure and function in an estrogen-dependent manner
Research protocols should account for estrogen levels or estrous cycling when investigating ADCYAP1R1 function
These findings suggest an important interaction between ADCYAP1R1 signaling and sex hormones that may contribute to sex differences in stress-related disorders, particularly PTSD.
Multiple lines of evidence implicate ADCYAP1R1 in PTSD vulnerability:
The current evidence indicates that ADCYAP1R1 represents an intermediate phenotype positioned between genetic risk factors and clinical outcomes, with brain structure and function reflecting an aggregate of genetic and environmental factors relevant to PTSD risk .
Optimal experimental designs for investigating ADCYAP1R1's role in fear processing should incorporate:
Imaging approaches:
Genotype considerations:
Physiological measures:
Controlling for confounding variables:
The study by PNAS demonstrated the value of this approach by matching genotype groups for trauma exposure and symptom severity, thereby isolating the independent effects of ADCYAP1R1 genotype on neural function .
Research on ADCYAP1R1 has several important implications for PTSD treatment:
Plasticity-based interventions:
Personalized treatment approach:
Genotyping patients for ADCYAP1R1 variants might predict treatment response
Those with the risk genotype might require modified therapeutic protocols to overcome plasticity deficits
Potential pharmacological targets:
The PACAP-PAC1 system could represent a novel target for PTSD therapeutics
Compounds enhancing PACAP signaling or bypassing deficient plasticity mechanisms might benefit risk genotype carriers
Research priorities:
Researchers investigating ADCYAP1R1 should be aware of several methodological challenges:
Sample size considerations:
Intermediate phenotype approach:
Multiple levels of analysis:
Sex-specific effects:
Population stratification:
While the search results focus primarily on genetic aspects of ADCYAP1R1 function, several points suggest important gene-environment interactions:
Trauma exposure:
Epigenetic mechanisms:
Hormonal environment:
Neural plasticity:
Based on the current state of knowledge, several research directions appear particularly promising:
Neural plasticity mechanisms:
Multi-level analysis:
Sex-specific mechanisms:
Larger samples with diverse populations:
Expanding beyond the relatively small, specific samples used in current research
Examining whether findings generalize across different ethnic and demographic groups
Circuit-level analysis:
Based on published methodology, researchers investigating ADCYAP1R1-related functional connectivity should consider the following protocol elements:
Task-based functional connectivity approach:
Control for confounding factors:
Model individual participants' motion parameters as nuisance covariates
Control for spontaneous, non-task-related covariance between regions by examining statistical contrasts (e.g., fearful vs. neutral stimuli)
Include only regions showing significantly increased connectivity with the amygdala for fearful relative to neutral faces
ROI selection:
Analysis approach:
This methodology has successfully identified reduced functional connectivity between the amygdala and hippocampus in carriers of the ADCYAP1R1 risk genotype .
Effective experimental designs for investigating ADCYAP1R1's role in fear learning should incorporate:
Participant selection:
Fear conditioning paradigms:
Imaging protocols:
Additional measures:
Analysis considerations:
While the search results focus primarily on neural expression, they also indicate important considerations for studying ADCYAP1R1 in other tissues:
Bone marrow research:
Autonomic nervous system connections:
Methodological approaches:
Experimental design:
This broader perspective on ADCYAP1R1 function highlights its diverse physiological roles beyond neural circuits and suggests important areas for translational research.